JACKSON T. WRIGHT, JR., MD, PhD, FACP
Case Western Reserve School of Medicine
Cleveland, Ohio
Jackson T. Wright, Jr., MD, PhD, FACP is professor of medicine, Division of Hypertension at Case Western Reserve University (CWRU) and director of the Clinical Hypertension Program at CWRU/University Hospitals of Cleveland. In addition, he is chief of the Hypertension Section at the Louis Stokes Cleveland VA Medical Center.
Dr. Wright grew up in Pittsburgh, Penn., received his bachelor of arts degree from Ohio Wesleyan University, and became the first Black to earn both an MD and PhD (Pharmacology) from the University of Pittsburgh School of Medicine. His housestaff training in Internal Medicine was performed at the University of Michigan. In addition to being board-certified in Internal Medicine, he was one of the first in the country to receive subspecialty board certification in Clinical Pharmacology. Prior to moving to CWRU in 1990, he served on the faculty in Clinical Pharmacology for 10 years at the Medical College of Virginia.
An experienced clinical investigator, Dr. Wright's primary research interest is in the clinical pharmacology of antihypertensive and cholesterol-lowering agents, especially in minority populations. Among his many professional affiliations in addition to ISHIB, he is fellow of the American College of Physicians, the Council for High Blood Pressure Research of the American Heart Association, and the Association of Black Cardiologists.
He has published extensively (more than 130 articles, book chapters, and abstracts) and served on many national and international advisory panels. Among these he currently serves on the National High Blood Education Program Coordinating Committee, the NIH advisory panel responsible for coordinating high blood pressure control efforts in the US. He is also vice chair of the Steering Committee for the NIH-sponsored AASK Trial, on which he also chaired the Design Subcommittee, and is principal investigator for the CWRU Clinical Center. This trial in 1,100 patients is currently evaluating the best treatment to prevent the most common cause of kidney failure in the Black community. In addition, he was selected to chair the Executive Committee and serve as vice chair of the Steering Committee for the largest-ever-conducted study of the treatment of high blood pressure and cholesterol, the ALLHAT study. This NIH-sponsored 7-year trial has recruited 42,448 participants, including more than 15,100 African American at 623 sites in the United States, Canada, the US Virgin Islands, and Puerto Rico. ALLHAT is also the largest interventional trial ever conducted in African Americans. Dr. Wright has been a member of ISHIB since its founding.
|
|
|
